---
title: "HUAPONT LIFE SCIENCES: Expected net profit loss of 310 million to 217 million yuan in 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225343328.md"
description: "HUAPONT LIFE SCIENCES announced that it expects a net loss attributable to shareholders of the listed company of RMB 310 million to RMB 217 million from January 1, 2024, to December 31, 2024, a decrease of 202.61% to 171.83% compared to the same period last year. The net loss after deducting non-recurring gains and losses is expected to be RMB 350 million to RMB 257 million, a decrease of 243.99% to 205.73% compared to the same period last year. The basic earnings per share loss is expected to be RMB 0.157 per share to RMB 0.1099 per share"
datetime: "2025-01-17T11:35:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225343328.md)
  - [en](https://longbridge.com/en/news/225343328.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225343328.md)
generator: "portal-rs"
---

# HUAPONT LIFE SCIENCES: Expected net profit loss of 310 million to 217 million yuan in 2024

HUAPONT LIFE SCIENCES announced that it expects a net loss attributable to shareholders of the listed company of RMB 310 million to RMB 217 million for the period from January 1, 2024, to December 31, 2024, a decrease of 202.61% to 171.83% compared to the same period last year. The net loss after deducting non-recurring gains and losses is expected to be RMB 350 million to RMB 257 million, a decrease of 243.99% to 205.73% compared to the same period last year. The basic earnings per share loss is expected to be RMB 0.157 per share to RMB 0.1099 per share

### Related Stocks

- [002004.CN](https://longbridge.com/en/quote/002004.CN.md)

## Related News & Research

- [CSPC’s SYS6010 Wins Third Breakthrough Therapy Tag in High-Need Cancer Indications](https://longbridge.com/en/news/297638498.md)
- [RISE Robotics Awarded $100,000 MassVentures Grant to Accelerate Commercialization of Beltdraulic Technology](https://longbridge.com/en/news/297642626.md)
- [Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President](https://longbridge.com/en/news/297630906.md)
- [PharmaEssentia’s Besremi receives FDA approval for ET](https://longbridge.com/en/news/297630746.md)
- [00:01 ETNorth Carolina Approves Reimbursement of VR Therapy for Neurodivergent Residents Under NC Innovations Waiver](https://longbridge.com/en/news/297593314.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**